Event

A Hopeful Future for Rare Disease in Canada

Following this month’s Rare Disease Day, join Canada 2020 for an event bringing together industry experts, policy makers, and patient advocates to discuss Canada’s rare disease drug strategy, and how best to plan for the future.

The upcoming year could be a momentous one for Canadians impacted by rare diseases. In 2019, the Government of Canada committed to developing a National Strategy for Drugs for Rare Diseases, with an initial commitment of $1 billion over two years beginning in 2022-23. This presents a real opportunity for Canadian patients who have struggled to get access to affordable treatment.

Following this month’s Rare Disease Day, join Canada 2020 for an event bringing together industry experts, policy makers, and patient advocates to discuss Canada’s rare disease drug strategy, and how best to plan for the future.

Featured Participants

  • Dr. Aneal Khan

    Pediatrician and Medical Geneticist

    Biography
  • Durhane Wong-Rieger

    President CEO, Canadian Organization for Rare Disorders & Institute for Optimizing Health Outcomes

    Biography
  • Marcel Saulnier

    Associate, Santis Health

  • Suzanne McGurn

    President and Chief Executive Officer, CADTH

  • Dr. Michelle Mujoomdar

    Director, Specialty Pharmaceuticals, Health Canada

  • Francis Drouin

    Parliamentary Secretary to the Minister of Agriculture and Agri-Food

    Biography
  • Michelle Boudreau

    Executive Director, Office of Pharmaceutical Management Strategies, Health Canada

  • Whitney Goulstone

    Executive Director, Canadian Immunodeficiencies Patient Organization

  • Dr. Stephen Betschel

    Departmental Division Director of Clinical Immunology, Department of Medicine, University of Toronto

  • Jo De Cock

    Senior Adviser, National Institute of Health and Disability Insurance (INAMI-RIZIV)

  • Rute Fernandes

    Executive Director, Takeda Canada

In partnership with

  • Takeda